February 10, 2021 - Treatment with the investigative gene cell therapy betibeglogene autotemcel led to durable transfusion independence in 87% of pediatric patients less than 18 years of age with transfusion-dependent beta-thalassemia with a median average hemoglobin of 11.3 g/dL.
February 10, 2021 - CPX-351 demonstrated improved overall survival at 5 years versus standard 7+3 chemotherapy in older patients with newly diagnosed high-risk or secondary acute myeloid leukemia.
February 10, 2021 - The JAK 1/2 inhibitor ruxolitinib, when given at a maximum dose of 10 mg peri-transplant, has been shown to be safe and feasible in patients with myelofibrosis.
February 9, 2021 - Responsiveness to treatment received immediately prior to CAR T-cell therapy may not be associated with post–CAR T outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma who receive axicabtagene ciloleucel.
Sairah Ahmed, MD, discusses the efficacy of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with refractory large B-cell lymphoma (LBCL) who achieved complete remission (CR) to any prior treatment versus those who were primary refractory.
Mitchell E. Horwitz, MD, discusses the use of omidubicel versus standard myeloablative umbilical cord blood transplant in patients with hematologic malignancies.
February 9, 2021 - Patients with refractory large B-cell lymphoma have less to gain from axicabtagene ciloleucel if they have never achieved a complete response to any line of prior therapy.
February 9, 2021 - Ruxolitinib, when administered using a pediatric dosing algorithm, was found to elicit responses in patients with chronic graft-versus-host disease with acceptable safety.
February 9, 2021 - JSP191 in combination with low-dose total body irradiation and fludarabine has demonstrated efficacy and tolerability in older patients with minimal residual disease–positive acute myeloid leukemia and myelodysplastic syndrome who are undergoing nonmyeloablative allogeneic hematopoietic cell transplantation.
February 8, 2021 — Narsoplimab demonstrated clinical activity and a favorable survival benefit in patients with high-risk hematopoietic stem cell transplant-associated thrombotic microangiopathy, according to updated results of a pivotal phase 2 trial.
With the emergence of multiple immunotherapy approaches in recent years, the decision of whether to use a single agent, to pair it with chemotherapy, or to pair it with another immunotherapy agent has come to the forefront of treatment.
Julie R. Brahmer, MD, discusses factors to consider when determining when to initiate immunotherapy in a patient with newly diagnosed non–small cell lung cancer.
Luis E. Raez, MD, discusses the potential utility of cemiplimab-rwlc in non–small cell lung cancer.
Vincent Lam, MD, describes frontline indications for this patient population, as well as strategies that can be utilized to overcome TKI resistance in later lines of therapy.
February 8, 2021 - Prior exposure to anti-CD19 therapy did not impact response to the CAR T-cell therapy lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.
February 8, 2021 - These findings may have implications for patients with hematologic malignancies, suggesting the development of protective memory against SARS-CoV2 and non-SARS human coronaviruses.
Now that a new standard of care has been established in frontline mesothelioma, clinical trials are needed to evaluate optimal sequencing with checkpoint inhibitors in the salvage setting and determine whether biomarkers of response to immunotherapy could further tailor treatment to individual patients.
Synergizing EGFR TKIs with antiangiogenic agents and chemotherapy, as well as improving the use of molecular classification, are novel strategies aimed at taking the frontline setting for patients with EGFR-mutant non–small cell lung cancer to the next level.
Mark A. Socinski, MD, discusses the nuances of the PACIFIC trial and ongoing research with durvalumab that could extend the reach of immunotherapy in early-stage lung cancer.
Over the past 2 decades, the field of EGFR-mutated non–small cell lung cancer has grown tremendously, but the influx of data and the recent regulatory approval of adjuvant osimertinib have raised several important questions to be addressed to ensure that the optimal treatment approach is utilized.
Rogerio C. Lilenbaum, MD, discusses some of the key clinical issues facing the lung cancer field, the role of genomic testing and multidisciplinary care, and the challenges that arose with telemedicine during the coronavirus disease 2019 pandemic.
In the quest for scientific purity, one should not lose sight of the meaningful end points that can make a difference in patients’ daily lives.
Mary Jo J. Fidler, MD, discusses the potential utility of circulating tumor DNA to inform treatment escalation in lung cancer.
Rogerio C. Lilenbaum, MD, discusses the challenges of integrating telehealth services in lung cancer.
Mark A. Socinski, MD, discusses the role of immunotherapy in PD-L1–negative lung cancer.
Hossein Borghaei, DO, MS, discusses selecting between single-agent versus combination therapies in lung cancer.
January 31, 2021 - Repotrectinib, a next-generation ROS1 and TRK TKI, has demonstrated encouraging objective responses with acceptable tolerability in patients with ROS1 fusion–positive non–small cell lung cancer.
January 31, 2021 - The latest data from the IMpower133 trial shows that maintenance therapy with atezolizumab plus carboplatin and etoposide improves overall survival and progression-free survival for patients with extensive stage small cell lung cancer.
Tepotinib demonstrated durable clinical activity in patients with MET exon 14 skipping non‒small cell lung cancer.
Byoung Chul Cho, MD, PhD, discusses the updated efficacy reported with repotrectinib in TKI-naïve patients with ROS1-positive non–small cell lung cancer.
